Prevention of tumors of the large intestine by celecoxib in mice.
Celecoxib (C), a COX-2 enzyme inhibitor, was administered at a 0.1% dose level in the diet of female Swiss Webster CFW outbred mice for life. The mice also received 1,2-dimethylhydrazine dihydrochloride (1,2-DMH) as 10 weekly subcutaneous injections at 20 microg/g body weight. The number of animals with large intestinal cancer and the total number of these cancers were 30 and 321 in the 1,2-DMH-treated group, while the corresponding figures in the C and 1,2-DMH-treated group were 29 and 156. This difference is statistically highly significant. The literature contains a limited number of publications concerning the cancer chemopreventive activity of C, particularly in mice. The present work, thus, provides additional proof in this field of interest.
Coles
Melissa
M
The Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA.
Toth
Bela
B
D000230:Adenocarcinoma / Q000139:chemically induced / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D000236:Adenoma / Q000139:chemically induced / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D000284:Administration, Oral; D000818:Animals; D021461:Animals, Outbred Strains; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004032:Diet; D004195:Disease Models, Animal; D004354:Drug Screening Assays, Antitumor; D005260:Female; D007093:Imidazoles / Q000633:toxicity; D007414:Intestinal Neoplasms / Q000139:chemically induced / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D008136:Longevity / Q000187:drug effects; D051379:Mice; D011720:Pyrazoles / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D015996:Survival Rate
D016588:Anticarcinogenic Agents; D016861:Cyclooxygenase Inhibitors; D007093:Imidazoles; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib; C032654:1,2-dimethylimidazole